Llwytho...
Application of anti-Sclerostin therapy in non-osteoporosis disease models
Sclerostin, a known inhibitor of the low density lipoprotein related protein 5 and 6 (LRP5 and LRP6) cell surface signaling receptors, is integral in the maintenance of normal bone mass and strength. Patients with loss of function mutations in SOST or missense mutations in LRP5 that prevent Sclerost...
Wedi'i Gadw mewn:
| Cyhoeddwyd yn: | Bone |
|---|---|
| Prif Awdur: | |
| Fformat: | Artigo |
| Iaith: | Inglês |
| Cyhoeddwyd: |
2016
|
| Pynciau: | |
| Mynediad Ar-lein: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5328800/ https://ncbi.nlm.nih.gov/pubmed/27780792 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.bone.2016.10.018 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|